Serum 99th percentile reference limits for cardiac troponin vary widely depending on the assay used, highlighting the need for assay-specific cutoffs and consideration of gender and ethnic differences.
Answers are grounded in this paper and cite their sources.
Assay-specific cTnI thresholds required for interpretation; cross-sectional data leaves open prospective validation of gender and ethnic adjustments.
Several international expert panels, including the European Society of Cardiology, the American College of Cardiology, American Heart Association, the IFCC, the COURAGE trials group, the Italian Federation of Cardiology, and the American Heart Association and World Heart Federation Councils on Epidemiology and Prevention, have endorsed the concept that increased cardiac troponin I or T (cTnI or cTnT) should be defined as a measurement above the 99th percentile concentration of a reference population (1)(2)(3)(4)(5)(6)(7). Furthermore, an increased cTnI or cTnT value is considered indicative of myocardial injury (cell death) and, in the clinical setting of ischemia, is considered evidence of myocardial infarction and a high-risk profile for adverse cardiac and noncardiac events. Previously, work from our laboratory reported on heparin plasma 99th percentile reference limits for both cTnT and seven cTnI assays (8). However, because heparin plasma is known to cause a negative bias compared with some, but not all cTnI and cTnT assays, reference limit determinations in serum would also be useful because serum and heparin plasma are the most commonly used specimen types in clinical practice. Preanalytical considerations suggest the use of plasma for reducing turnaround times. In addition, a recent study of imprecision for cardiac troponin assays to determine the lowest concentration that meets a 10% total imprecision (CV) was predicated on serum (9), with the goal to assess the size of the gap between the 99th percentile reference limit and the lowest troponin concentration that provides a 10% CV. Although several studies have published serum-based 99th percentile reference limits for individual assays, no study has used the same population to evaluate reference limits for numerous cardiac troponin assays. The purpose of this study was to determine (using nonparametric statistics) the 99th percentile reference limit, based on samples from 403 healthy volunteers. After receiving Institutional Review Board approval and having participants complete a health questionnaire ruling out any past or current history of heart disease, we collected nonanticoagulated blood (Becton Dickinson Vacutainer SST Gel and Clot Activator tube), separated the serum, and froze it at −70 °C. We recruited 215 females (53%) and 188 (47%) males, of whom 168 were African American (42%), 181 were Caucasian (45%), and 54 were of other ethnicities (13%). Ages ranged from 30 to 84 years (median, 49 years). As shown in Table 1 , not all assays were performed on all samples because of limited specimen volumes. To verify lack of interference by heterophile antibodies, we screened selected samples with high cardiac troponin by a commercial heterophile antibody blocking system (Scantibodies Laboratories). Shown in Table 1 are the serum 99th percentile limits for six cTnI assays and one cTnT assay for all participants, as well as a breakdown for males and females. Serum 99th percentile reference limits by gender and ethnicity for Food and Drug Administration-cleared cardiac troponin assays. Not all assays were performed on all samples because of insufficient sample volume. The number of samples assayed with the Tosoh and Bayer assays are shown in parentheses when they differ from the number of samples tested by the other assays. Only cTnT assay on the marketplace; all other assays are for cTnI. Significantly different (P = 0.05) vs Caucasians based on mean concentrations. Serum 99th percentile reference limits by gender and ethnicity for Food and Drug Administration-cleared cardiac troponin assays. Not all assays were performed on all samples because of insufficient sample volume. The number of samples assayed with the Tosoh and Bayer assays are shown in parentheses when they differ from the number of samples tested by the other assays. Only cTnT assay on the marketplace; all other assays are for cTnI. Significantly different (P = 0.05) vs Caucasians based on mean concentrations. For cTnI, the reference limits ranged from 0.03 μg/L (Dade Dimension) to 1.1 μg/L (Abbott AxSYM), a 36-fold difference. We found significant differences between males and females for the Beckman Access, Ortho cTnI Vitros ECi, and Bayer Centaur cTnI assays. All cTnT concentrations were ≤0.015 μg/L, with the overall 99th percentile limit being <0.01 μg/L. Only the Ortho Vitros ECi cTnI showed a significant difference by ethnicity. Our results for serum are similar to those obtained in our previous study on 99th percentile reference limits for plasma (8): (a) results obtained with different cTnI assays vary considerably because of differences in standardization and in the antibodies used (10); and (b) there is evidence of gender and ethnic variation. In general, the current serum reference concentrations (n ≤403 individuals) compared with our previous plasma findings in a larger population (n ≤696 individuals) were not predictably higher for all assays, as has been suggested in several Food and Drug Administration-cleared package inserts and previous literature (4)(8)(11)(12). The findings also demonstrate that only one of seven assays (Beckman) gave a 99th percentile concentration (0.05 μg/L) close to the previously reported total 10% imprecision concentration (0.06 μg/L) (9). Thus it is possible that some of the gender differences may be related to assay imprecision. A limitation of this study, however, was that matched serum and plasma samples were not available for analysis. Overall, our findings add to the literature to assist in setting reference limits for the cardiac troponin assays available from the major in vitro diagnostic manufacturers. Further investigations are necessary to explore gender and ethnic differences that may impact diagnostic or risk stratification decisions in patients with acute coronary syndrome (13)(14)(15)(16)(17).
No takes yet. Share an insight, caveat, or question.
MaryAnn M. Murakami (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: